CONTEXT: Optimal treatment to postpone functional decline in patients with dementia is not established. OBJECTIVE: To test a nonpharmacologic intervention realigning environmental demands with patient capabilities. DESIGN, SETTING, AND PARTICIPANTS: Prospective 2-group randomized trial (Care of Persons with Dementia in their Environments [COPE]) involving patients with dementia and family caregivers (community-living dyads) recruited from March 2006 through June 2008 in Pennsylvania. INTERVENTIONS: Up to 12 home or telephone contacts over 4 months by health professionals who assessed patient capabilities and deficits; obtained blood and urine samples; and trained families in home safety, simplifying tasks, and stress reduction. Control group caregivers received 3 telephone calls and educational materials. MAIN OUTCOME MEASURES: Functional dependence, quality of life, frequency of agitated behaviors, and engagement for patients and well-being, confidence using activities, and perceived benefits for caregivers at 4 months. RESULTS:Of 284 dyads screened, 270 (95%) were eligible and 237 (88%) randomized. Data were collected from 209 dyads (88%) at 4 months and 173 (73%) at 9 months. At 4 months, compared with controls, COPE patients had less functional dependence (adjusted mean difference, 0.24; 95% CI, 0.03-0.44; P = .02; Cohen d = 0.21) and less dependence in instrumental activities of daily living (adjusted mean difference, 0.32; 95% CI, 0.09-0.55; P = .007; Cohen d = 0.43), measured by a 15-item scale modeled after the Functional Independence Measure; COPE patients also had improved engagement (adjusted mean difference, 0.12; 95% CI, 0.07-0.22; P = .03; Cohen d = 0.26), measured by a 5-item scale. COPE caregivers improved in their well-being (adjusted mean difference in Perceived Change Index, 0.22; 95% CI, 0.08-0.36; P = .002; Cohen d = 0.30) and confidence using activities (adjusted mean difference, 0.81; 95% CI, 0.30-1.32; P = .002; Cohen d = 0.54), measured by a 5-item scale. By 4 months, 64 COPE dyads (62.7%) vs 48 control group dyads (44.9%) eliminated 1 or more caregiver-identified problems (chi(2/1) = 6.72, P = . 01). CONCLUSION: Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. Although no group differences were observed at 9 months for patients, COPE caregivers perceived greater benefits. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00259454.
RCT Entities:
CONTEXT: Optimal treatment to postpone functional decline in patients with dementia is not established. OBJECTIVE: To test a nonpharmacologic intervention realigning environmental demands with patient capabilities. DESIGN, SETTING, AND PARTICIPANTS: Prospective 2-group randomized trial (Care of Persons with Dementia in their Environments [COPE]) involving patients with dementia and family caregivers (community-living dyads) recruited from March 2006 through June 2008 in Pennsylvania. INTERVENTIONS: Up to 12 home or telephone contacts over 4 months by health professionals who assessed patient capabilities and deficits; obtained blood and urine samples; and trained families in home safety, simplifying tasks, and stress reduction. Control group caregivers received 3 telephone calls and educational materials. MAIN OUTCOME MEASURES: Functional dependence, quality of life, frequency of agitated behaviors, and engagement for patients and well-being, confidence using activities, and perceived benefits for caregivers at 4 months. RESULTS: Of 284 dyads screened, 270 (95%) were eligible and 237 (88%) randomized. Data were collected from 209 dyads (88%) at 4 months and 173 (73%) at 9 months. At 4 months, compared with controls, COPE patients had less functional dependence (adjusted mean difference, 0.24; 95% CI, 0.03-0.44; P = .02; Cohen d = 0.21) and less dependence in instrumental activities of daily living (adjusted mean difference, 0.32; 95% CI, 0.09-0.55; P = .007; Cohen d = 0.43), measured by a 15-item scale modeled after the Functional Independence Measure; COPE patients also had improved engagement (adjusted mean difference, 0.12; 95% CI, 0.07-0.22; P = .03; Cohen d = 0.26), measured by a 5-item scale. COPE caregivers improved in their well-being (adjusted mean difference in Perceived Change Index, 0.22; 95% CI, 0.08-0.36; P = .002; Cohen d = 0.30) and confidence using activities (adjusted mean difference, 0.81; 95% CI, 0.30-1.32; P = .002; Cohen d = 0.54), measured by a 5-item scale. By 4 months, 64 COPE dyads (62.7%) vs 48 control group dyads (44.9%) eliminated 1 or more caregiver-identified problems (chi(2/1) = 6.72, P = . 01). CONCLUSION: Among community-living dyads, a nonpharmacologic biobehavioral environmental intervention compared with control resulted in better outcomes for COPE dyads at 4 months. Although no group differences were observed at 9 months for patients, COPE caregivers perceived greater benefits. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00259454.
Authors: R G Logsdon; L Teri; M F Weiner; L E Gibbons; M Raskind; E Peskind; M Grundman; E Koss; R G Thomas; L J Thal Journal: J Am Geriatr Soc Date: 1999-11 Impact factor: 5.562
Authors: Linda Teri; Laura E Gibbons; Susan M McCurry; Rebecca G Logsdon; David M Buchner; William E Barlow; Walter A Kukull; Andrea Z LaCroix; Wayne McCormick; Eric B Larson Journal: JAMA Date: 2003-10-15 Impact factor: 56.272
Authors: Richard Schulz; Alison O'Brien; Sara Czaja; Marcia Ory; Rachel Norris; Lynn M Martire; Steven H Belle; Lou Burgio; Laura Gitlin; David Coon; Robert Burns; Dolores Gallagher-Thompson; Alan Stevens Journal: Gerontologist Date: 2002-10
Authors: Minna K Löppönen; Raimo E Isoaho; Ismo J Räihä; Tero J Vahlberg; Saila M Loikas; Timo I Takala; Hannu Puolijoki; Kerttu M Irjala; Sirkka-Liisa Kivelä Journal: Dement Geriatr Cogn Disord Date: 2004-08-06 Impact factor: 2.959
Authors: Richard H Fortinsky; Laura N Gitlin; Laura T Pizzi; Catherine Verrier Piersol; James Grady; Julie T Robison; Sheila Molony Journal: Contemp Clin Trials Date: 2016-07-06 Impact factor: 2.226
Authors: Alycia A Bristol; Kimberly A Convery; Victor Sotelo; Catherine E Schneider; Shih-Yin Lin; Jason Fletcher; Randall Rupper; James E Galvin; Abraham A Brody Journal: Contemp Clin Trials Date: 2020-04-19 Impact factor: 2.226
Authors: Laura N Gitlin; Katherine Marx; Daniel Scerpella; Holly Dabelko-Schoeny; Keith A Anderson; Jin Huang; Laura Pizzi; Eric Jutkowitz; David L Roth; Joseph E Gaugler Journal: Contemp Clin Trials Date: 2019-06-22 Impact factor: 2.226
Authors: Germaine Odenheimer; Soo Borson; Amy E Sanders; Rebecca J Swain-Eng; Helen H Kyomen; Samantha Tierney; Laura N Gitlin; Mary Ann Forciea; John Absher; Joseph Shega; Jerry Johnson Journal: Neurology Date: 2013-09-25 Impact factor: 9.910
Authors: Ann Kolanowski; Richard H Fortinsky; Margaret Calkins; Davangere P Devanand; Elizabeth Gould; Tamar Heller; Nancy A Hodgson; Helen C Kales; Jeffrey Kaye; Constantine Lyketsos; Barbara Resnick; Melanie Schicker; Sheryl Zimmerman Journal: J Am Med Dir Assoc Date: 2018-08-23 Impact factor: 4.669
Authors: Judith T Matthews; Jennifer H Lingler; Grace B Campbell; Amanda E Hunsaker; Lu Hu; Bernardo R Pires; Martial Hebert; Richard Schulz Journal: J Healthc Eng Date: 2015 Impact factor: 2.682